FDA Approves First Gene Therapy for Genetic Deafness

A mother in America can finally tell her son she loves him and watch him understand every word.

Two-and-a-half-year-old Travis Smith was born with a rare genetic mutation that left him completely deaf. But after receiving Regeneron's experimental gene therapy at 18 months old, everything changed. "Watching him be able to interact with other children and even him knowing his name now and turning when I say his name is the craziest thing," his mother Sierra said.

On Thursday, the FDA approved that same therapy called Otarmeni, making it the first gene therapy ever available for genetic hearing loss. The approval opens a new door for 20 to 50 babies born in the U.S. each year with this specific condition.

The therapy targets a mutation in the OTOF gene, which normally produces a protein called otoferlin. This protein acts like a messenger in the inner ear, helping transmit sound signals to the brain. When the gene doesn't work properly, children are born profoundly deaf.

Otarmeni works by delivering a healthy copy of the OTOF gene directly into the cochlea, the snail-shaped cavity in the inner ear. Doctors use a modified, harmless virus to carry the working gene to exactly where it's needed. Once there, the gene starts producing the missing protein, essentially giving the ear the tools it needs to hear.

Regeneron announced the treatment will be completely free for U.S. patients, removing financial barriers for families facing this diagnosis. The company is also set to announce a drug pricing agreement with the White House to formalize this commitment.

Why This Inspires

This approval represents more than help for one rare condition. It signals a turning point in how we think about treating hearing loss altogether.

"I'd say for the field, it means a new era in thinking about treatments for hearing loss. This is just the beginning," said Jonathon Whitton, Regeneron's auditory global program head. Other companies including China's Refreshgene and Eli Lilly are already studying similar therapies that have shown promising results in early trials.

For Sierra and families like hers, the science translates into something much simpler and more profound. "I can tell him how much I love him," she said. "It's such a different world."